Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of PEG Somatropin Injection (Jintrolong®) in the
treatment of short stature due to endogenous growth hormone deficiency (GHD) in the broad of
population of children.
Phase:
Phase 4
Details
Lead Sponsor:
GeneScience Pharmaceuticals Co., Ltd.
Collaborators:
Central South University First Affiliated Hospital of Guangxi Medical University First People's Hospital of Hangzhou Guangzhou Women and Children's Medical Center Qilu Hospital Second Affiliated Hospital of Wenzhou Medical University Shanghai Children's Medical Center Shaoxing Second Hospital Southwest Hospital, China The Children's Hospital of Zhejiang University School of Medicine The First Affiliated Hospital of Xiamen University The Second Hospital of Anhui Medical University Third Affiliated Hospital, Sun Yat-Sen University Xiangya Hospital of Central South University Zhejiang Provincial Hospital of TCM Zhejiang Provincial People’s Hospital